Bharat Biotech Launches Hillchol: A New Oral Cholera Vaccine to Address Global Shortage
| Category | Details |
|---|---|
| Company | Bharat Biotech International Ltd |
| Product Launched | Hillchol (BBV131) - Oral Cholera Vaccine (OCV) |
| Global Demand for OCVs | Exceeds 100 million doses annually, deficit of approximately 40 million |
| Cholera Situation | Cases and deaths rising since 2021, urgent need for OCVs |
| Vaccine Administration | Oral, on Day 0 and Day 14 |
| Age Group | Suitable for individuals above one year of age |
| Storage Requirement | Between +2°C and +8°C |
| Manufacturing Capacity | Up to 200 million doses annually in Hyderabad and Bhubaneswar facilities |
| Collaborators | Hilleman Laboratories, University of Gothenburg, Gotovax AB |
| Global Goal Alignment | Global Task Force on Cholera Control's (GTFCC) goal of reducing cholera-related deaths by 90% by 2030 |
| Company Details | Founded: 1996, Headquarters: Hyderabad, India |
| Specialization | Vaccine development, production, and distribution |
| Notable Products | Covaxin, Rotavac, Typbar TCV, Hillchol |
| Global Impact | Supplies vaccines to over 123 countries |
| Research & Development | Innovative vaccine technologies with public and private sector partnerships |
| Regulatory Approvals | Approved by WHO and national regulatory authorities |
| Recent Achievement | Launched Hillchol in 2024 |